← All trials
NCT04789915
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 26, 2021
- Primary completion
- May 1, 2023
- Completion date
- Dec 31, 2024
- First posted
- Mar 10, 2021
- Last posted
- Aug 25, 2021
- Enrollment
- 46
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CopenhagenLead sponsor
- University of CopenhagenSponsor investigator
- University of CopenhagenCollaborator
- LundbeckCollaborator
- Danish Research Centre for Magnetic ResonanceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.